---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042893"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:56:06.200674+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint

## Summary
- Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
- GAAP diluted EPS $0.94; adjusted diluted EPS $1.21; FY 2024 adj. EPS guidance raised to $4.64-$4.70.
- FreeStyle Libre CGM sales >$1.6B (+20.7% organic); new $7B share repurchase authorized; quarterly dividend $0.55.
- Partnered with Medtronic to connect CGM with insulin devices; launched OTC Lingo CGM in U.S.; completed VOLT-AF trial enrollment.
- Nutrition organic +3.4% (Adult +9.1%); Diagnostics organic ex-COVID +3.3% (Core Lab +4.5%); Established Pharma organic +7.0%.

## SEC filing metadata
- accession: 0001628280-24-042893
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828024042893/0001628280-24-042893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828024042893/abt-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042893
- JSON: https://secwatch.observer/filing/0001628280-24-042893.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.